Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 5/20 | 0.55 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5187982 | 1.00 | CHRNB4 (0.55) | CHRNB4CHRNA3OPRM1OPRD1OPRK1 | |
| SCHEMBL13403254 | 1.00 | CHRNB4 (0.55) | CHRNB4CHRNA3OPRM1OPRD1OPRK1 | |
| SCHEMBL3538856 | 1.00 | CHRNB4 (0.55) | CHRNB4CHRNA3OPRM1OPRD1OPRK1 | |
| SCHEMBL31568823 | 1.00 | CHRNB4 (0.55) | CHRNB4CHRNA3OPRM1OPRD1OPRK1 | |
| SCHEMBL1797148 | 0.95 | CHRNB4 (0.50) | CHRNB4CHRNA3OPRM1OPRD1OPRK1 | |
| SCHEMBL1795653 | 0.95 | CHRNB4 (0.50) | CHRNB4CHRNA3OPRM1OPRD1OPRK1 | |
| SCHEMBL1794388 | 0.95 | CHRNB4 (0.50) | CHRNB4CHRNA3OPRM1OPRD1OPRK1 | |
| SCHEMBL1797151 | 0.95 | CHRNB4 (0.50) | CHRNB4CHRNA3OPRM1OPRD1OPRK1 | |
| SCHEMBL1795410 | 0.95 | CHRNB4 (0.50) | CHRNB4CHRNA3OPRM1OPRD1OPRK1 | |
| SCHEMBL13403267 | 0.93 | CHRNB4 (0.49) | CHRNB4CHRNA3OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700585-B2 | Derivatives of N-[phenyl(pyrrolidine-2-YL)methyl]benzamide and N-[(azepan-2-YL) phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2010-04-20 | — | — | US | disclosed |
| US-20070208006-A1 | DERIVATIVES OF N-[PHENYL(PYRROLIDINE-2-YL)METHYL]BENZAMIDE AND N-[(AZEPAN-2-YL)PHENYLMETHYL]BENZAMIDE, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-09-06 | — | — | US | disclosed |
| EP-1680400-B1 | DERIVATIVES OF N-[ PHENYL(PYRROLIDINE-2-YL)METHYL]BENZAMIDE AND N-[ (AZEPAN-2-YL)PHENYLMETHYL]BENZAMIDE, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2007-06-06 | — | — | EP | disclosed |
| US-7226917-B2 | Derivatives of N-[phenyl(pyrrolidine-2-yl)methyl]benzamide and N-[(azepan-2-yl)phenylmethyl]benzamide, preparation, and use in treatment of schizophrenia | SANOFI-AVENTIS (FR) | 2007-06-05 | — | — | US | disclosed |
| US-20060223802-A1 | Derivatives of N-[phenyl(pyrrolidine-2-yl)methyl]benzamide and N-[(azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208006-A1 | DERIVATIVES OF N-[PHENYL(PYRROLIDINE-2-YL)METHYL]BENZAMIDE AND N-[(AZEPAN-2-YL)PHENYLMETHYL]BENZAMIDE, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SNCA, CHRNA10, CHRNA5 | CHRNB4 71/4885CHRNA3 21/4885OPRM1 60/4885 |
| US-20060223802-A1 | Derivatives of N-[phenyl(pyrrolidine-2-yl)methyl]benzamide and N-[(azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics | SNCA, CHRNA10, CHRNA5 | CHRNB4 71/4885CHRNA3 21/4885OPRM1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.